Zoster Vaccine
On this page
Direct answer
Two doses of recombinant zoster vaccine (RZV, Shingrix), given intramuscularly 2–6 months apart, are the standard way to prevent herpes zoster and post-herpetic neuralgia in adults aged 50 years and above, with efficacy above 90% across age groups including the elderly. GSK launched Shingrix in India in April 2023 for adults aged 50 and older, making it available through private channels. Unlike the older live Zostavax, the recombinant vaccine is not contraindicated in most immunocompromised adults, for whom it is recommended from age 18 or 19 years per international guidance.
What you must remember
- RZV contains varicella zoster glycoprotein E with the AS01B adjuvant; it works by boosting T-cell immunity, so it can be given regardless of prior chickenpox or zoster.
- Schedule: 0 and 2–6 months, intramuscular, deltoid; if the second dose is delayed, give it without restarting the series.
- Efficacy above 90% against zoster and near 90% against post-herpetic neuralgia in adults over 50, with protection persisting well beyond 5 years and waning only gradually.
- The older live zoster vaccine (Zostavax) is far less effective, especially over age 70, and is contraindicated in immunosuppression; it has been withdrawn in many markets.
- Recombinant vaccine is preferred even in patients with prior zoster or existing post-herpetic neuralgia, but give it after the acute episode has resolved.
- Common side effects are local pain and transient fever or myalgia; grade 3 systemic symptoms occur in a minority and resolve in 1–2 days.
- It prevents zoster — it does not treat an active rash or established neuralgia, a distinction exams probe.
How to counsel three different patients
A healthy 55-year-old executive asks whether he needs the shot: yes, at 50 years the recommendation begins, and in India it is a self-paid vaccine since the national programme does not include it, so cost and availability in private hospitals matter. Explain the two-dose schedule, the roughly one-in-six chance of a fever day, and that even if he had shingles last year, vaccination after recovery still reduces recurrence. Next, a 62-year-old woman on methotrexate for rheumatoid arthritis: the recombinant vaccine is the correct choice precisely because it is non-live; international guidance supports RZV in immunocompromised adults from 18–19 years, ideally when immunosuppression is stable or before planned immunosuppression, and many Indian rheumatologists now administer it before starting biologics. Contrast her with a 70-year-old transplant candidate on the waiting list: vaccinate before transplantation, because responses are blunted afterwards, and time doses at least 2 weeks before immunosuppression where feasible. In all three, document that this vaccine does not replace the routine tetanus or influenza schedule and that it cannot cause chickenpox, since it contains no live virus — a frequent patient fear worth addressing directly.
How the exam frames it
NEET-PG-style questions frame zoster vaccination around contrasts: live versus recombinant, age cut-offs, and immunosuppression. The trap is assuming "all vaccines are contraindicated in immunosuppression" — that rule applies to live vaccines like Zostavax, measles and varicella, not to the recombinant product, which is specifically recommended for immunocompromised adults. A second framing is timing: an elderly patient with active zoster ophthalmicus asks for the vaccine "right now"; the answer is to wait until the acute lesions have crusted and the episode has settled. A third is the interval after varicella vaccine — because RZV is not live, there is no pregnancy issue to exploit, and it can even be given with influenza or pneumococcal vaccines at different sites. Expect one-line questions on adjuvant name (AS01B), dose count (two), and minimum age in routine use (50 years).
Frequently asked questions
What is the schedule of the recombinant zoster vaccine?
Two intramuscular doses, the second 2 to 6 months after the first; in immunocompromised patients a shorter 1–2 month interval may be used per guidance.
Can Shingrix be given to immunocompromised patients?
Yes, it is non-live and is recommended for immunocompromised adults aged 18 or 19 years and above in several national guidelines, ideally before intense immunosuppression begins.
Should a person with previous shingles receive zoster vaccine?
Yes — recurrence happens, and vaccination after recovery from an episode further reduces risk; wait until the acute rash and pain have subsided.
Is zoster vaccine available in India's national programme?
No; it is available privately since its Indian launch in 2023 for adults 50 years and above, and is not part of the Universal Immunisation Programme.
Can the vaccine cause chickenpox or shingles?
No; the recombinant vaccine contains only the glycoprotein E antigen with adjuvant, with no live virus capable of causing disease.